Here is the design of a clinical trial:

Official Title: A Multi-Center, Randomized, Single-Blind, Propofol-Controlled Phase III Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation

Included conditions:
- Sedation in Intensive Care

Study Armgroups:
- {'label': 'HSK3486', 'type': 'EXPERIMENTAL', 'description': 'HSK3486 for Sedation', 'interventionNames': ['Drug: HSK3486']}
- {'label': 'Propofol', 'type': 'ACTIVE_COMPARATOR', 'description': 'Propofol for Sedation', 'interventionNames': ['Drug: Propofol']}

Interventions:
- {'type': 'DRUG', 'name': 'HSK3486', 'description': 'Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h', 'armGroupLabels': ['HSK3486']}
- {'type': 'DRUG', 'name': 'Propofol', 'description': 'Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s\n\nMaintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:\n\n0.3-4 mg/kg/h', 'armGroupLabels': ['Propofol']}

Primary Outcomes:
- {'measure': 'Success rate of sedation', 'description': '1) The time period during which the RASS is in the range of +1 to -2 accounts for ≥ 70% of the total duration of study administration and 2) Remedial treatment is not used.', 'timeFrame': 'Within 24 hours of administration'}

Please estimate the sample size based on the assumption: 
Type I error (false positive) set at 0.025 (unilateral), power at 80%, and a 10% dropout rate
Sample Size
        This trial is designed as a non-inferiority objective study for MV sedation within 24Â h. Assuming the ciprofol study drug and propofol (the positive control drug) will have an ICU sedation success rate of 99%, the type I error (false positive) will be set at 0.025 (unilateral) and the power at 80%. The non-inferiority margin considered to be clinically acceptable will be set at 8%, with a required sample size of 120 patients, allowing for a 10% dropout rate. Thus, a total of 135 patients who will receive mechanical ventilation will be included from July 2020 to July 2022 in our ICU, based on random assignment at a ratio of 2:1 to the ciprofol (nâ=â90) or propofol control (nâ=â45) groups.